{"organizations": [], "uuid": "c7f81ffde6cba5c3dfb75d575954098f625b9165", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180307.html", "section_title": "Archive News &amp; Video for Wednesday, 07 Mar 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-ligand-pharma-says-underreported-p/brief-ligand-pharma-says-underreported-potential-aggregate-milestone-payments-related-to-license-agreement-with-roivant-sciences-idUSFWN1QP087", "country": "US", "domain_rank": 408, "title": "BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.188, "site_type": "news", "published": "2018-03-07T19:26:00.000+02:00", "replies_count": 0, "uuid": "c7f81ffde6cba5c3dfb75d575954098f625b9165"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-ligand-pharma-says-underreported-p/brief-ligand-pharma-says-underreported-potential-aggregate-milestone-payments-related-to-license-agreement-with-roivant-sciences-idUSFWN1QP087", "ord_in_thread": 0, "title": "BRIEF-Ligand Pharma Says‍ Underreported Potential Aggregate Milestone Payments Related To License Agreement With Roivant Sciences", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ligand pharmaceuticals inc", "sentiment": "negative"}, {"name": "sec", "sentiment": "none"}, {"name": "ligand pharma", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 7 (Reuters) - Ligand Pharmaceuticals Inc:\n* LIGAND PHARMACEUTICALS SAYS‍ UNDERREPORTED POTENTIAL AGGREGATE MILESTONE PAYMENTS RELATED TO LICENSE AGREEMENT WITH ROIVANT SCIENCES FOR LGD-6972​\n* LIGAND PHARMA SAYS UNDER AGREEMENT, CO TO RECEIVE POTENTIAL LICENSE & MILESTONE PAYMENTS OF UP TO $548.8 MILLION - SEC FILING Source text: ( bit.ly/2I7Qw0U ) Further company coverage:\n ", "external_links": ["http://bit.ly/2I7Qw0U", "http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-03-07T19:26:00.000+02:00", "crawled": "2018-03-08T17:21:20.000+02:00", "highlightTitle": ""}